DXCM vs LLY: fair value comparison
DexCom, Inc. and Eli Lilly and Company · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking.
| DXCM | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $83.03 | $1,115.70 |
| 12-month range | $58.22–$90.14 | $862.86–$1,160.00 |
| Sector rank | #19 of 113 Healthcare | #14 of 113 Healthcare |
| Quality grade | B | B |
| Momentum grade | B | — |
| Leverage | Moderate | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: DXCM fair value analysis · LLY fair value analysis